News and Announcements
BPS Trading Update and Profit Guidance
- Published October 27, 2016 12:34PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th October 2016, ASX Announcement
Highlights of 1HFY17 guidance:
- 120% increase in revenue against the prior six month period
- 48% increase in EBITDA against the prior six month period
- 15% increase in earnings per share against the prior six month period
- The $5m Convertible Note that was issued in December 2015 will be redeemed on 12 December 2016
BPS Technology Limited “BPS” (ASX:BPS) is pleased to update the market on the outlook for the first half of FY17 after a better than expected first quarter. The upcoming half-year results will be the first that include the acquisition of Entertainment Publications of Australia and New Zealand “EPANZ” as announced to the market on 12 August 2016.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
